717 related articles for article (PubMed ID: 11978335)
1. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
[TBL] [Abstract][Full Text] [Related]
2. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
Hague W; Forder P; Simes J; Hunt D; Tonkin A;
Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
[TBL] [Abstract][Full Text] [Related]
3. Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease).
White HD; Tonkin A; Simes J; Stewart R; Mann K; Thompson P; Colquhoun D; West M; Nestel P; Sullivan D; Keech AC; Hunt D; Blankenberg S;
J Am Coll Cardiol; 2014 Feb; 63(4):345-54. PubMed ID: 24140630
[TBL] [Abstract][Full Text] [Related]
4. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?
Simes RJ; Marschner IC; Hunt D; Colquhoun D; Sullivan D; Stewart RA; Hague W; Keech A; Thompson P; White H; Shaw J; Tonkin A;
Circulation; 2002 Mar; 105(10):1162-9. PubMed ID: 11889008
[TBL] [Abstract][Full Text] [Related]
5. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.
Hunt D; Young P; Simes J; Hague W; Mann S; Owensby D; Lane G; Tonkin A
Ann Intern Med; 2001 May; 134(10):931-40. PubMed ID: 11352694
[TBL] [Abstract][Full Text] [Related]
6. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Cannon CP; Braunwald E; McCabe CH; Rader DJ; Rouleau JL; Belder R; Joyal SV; Hill KA; Pfeffer MA; Skene AM;
N Engl J Med; 2004 Apr; 350(15):1495-504. PubMed ID: 15007110
[TBL] [Abstract][Full Text] [Related]
7. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
N Engl J Med; 1998 Nov; 339(19):1349-57. PubMed ID: 9841303
[TBL] [Abstract][Full Text] [Related]
8. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease.
Nestel PJ; Barnes EH; Tonkin AM; Simes J; Fournier M; White HD; Colquhoun DM; Blankenberg S; Sullivan DR
Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2902-8. PubMed ID: 24092750
[TBL] [Abstract][Full Text] [Related]
9. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
[TBL] [Abstract][Full Text] [Related]
10. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project.
Simes J; Furberg CD; Braunwald E; Davis BR; Ford I; Tonkin A; Shepherd J
Eur Heart J; 2002 Feb; 23(3):207-15. PubMed ID: 11792135
[TBL] [Abstract][Full Text] [Related]
11. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico).
Ital Heart J; 2000 Dec; 1(12):810-20. PubMed ID: 11302109
[TBL] [Abstract][Full Text] [Related]
12. Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial.
Thompson PL; Meredith I; Amerena J; Campbell TJ; Sloman JG; Harris PJ;
Am Heart J; 2004 Jul; 148(1):e2. PubMed ID: 15215811
[TBL] [Abstract][Full Text] [Related]
13. Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study.
Tonkin AM; Colquhoun D; Emberson J; Hague W; Keech A; Lane G; MacMahon S; Shaw J; Simes RJ; Thompson PL; White HD; Hunt D
Lancet; 2000 Dec; 356(9245):1871-5. PubMed ID: 11130382
[TBL] [Abstract][Full Text] [Related]
14. Pravastatin in acute ischaemic syndromes: results of a randomised placebo-controlled trial.
Den Hartog FR; Van Kalmthout PM; Van Loenhout TT; Schaafsma HJ; Rila H; Verheugt FW
Int J Clin Pract; 2001 Jun; 55(5):300-4. PubMed ID: 11452676
[TBL] [Abstract][Full Text] [Related]
15. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
[TBL] [Abstract][Full Text] [Related]
16. C-reactive protein levels and outcomes after statin therapy.
Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E;
N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109
[TBL] [Abstract][Full Text] [Related]
17. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.
Lewis SJ; Sacks FM; Mitchell JS; East C; Glasser S; Kell S; Letterer R; Limacher M; Moye LA; Rouleau JL; Pfeffer MA; Braunwald E
J Am Coll Cardiol; 1998 Jul; 32(1):140-6. PubMed ID: 9669262
[TBL] [Abstract][Full Text] [Related]
18. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of the West of Scotland Coronary Prevention Study.
Ford I; Murray H; Packard CJ; Shepherd J; Macfarlane PW; Cobbe SM;
N Engl J Med; 2007 Oct; 357(15):1477-86. PubMed ID: 17928595
[TBL] [Abstract][Full Text] [Related]
20. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
Lancet; 2003 Apr; 361(9364):1149-58. PubMed ID: 12686036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
